UY33164A - Metodo de tratamiento - Google Patents

Metodo de tratamiento

Info

Publication number
UY33164A
UY33164A UY0001033164A UY33164A UY33164A UY 33164 A UY33164 A UY 33164A UY 0001033164 A UY0001033164 A UY 0001033164A UY 33164 A UY33164 A UY 33164A UY 33164 A UY33164 A UY 33164A
Authority
UY
Uruguay
Prior art keywords
treatment method
treatment
hydrates
administration
patient
Prior art date
Application number
UY0001033164A
Other languages
English (en)
Inventor
Valeriu Damian-Iordache
King Andrew
Megan M Mclaughlin
Andrew B Suttle
Original Assignee
Glaxo Wellcome Mfg Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Wellcome Mfg Pte Ltd filed Critical Glaxo Wellcome Mfg Pte Ltd
Publication of UY33164A publication Critical patent/UY33164A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

La presente invención se refiere a métodos para el tratamiento de trastornos de angiogénesis ocular o filtración vascular en un paciente, mediante la administración de inhibidores adecuados, incluyendo pazopanib o sales farmacéuticamente aceptables o hidratos del mismo.
UY0001033164A 2010-01-06 2011-01-04 Metodo de tratamiento UY33164A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29274710P 2010-01-06 2010-01-06

Publications (1)

Publication Number Publication Date
UY33164A true UY33164A (es) 2011-08-31

Family

ID=44305773

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033164A UY33164A (es) 2010-01-06 2011-01-04 Metodo de tratamiento

Country Status (20)

Country Link
US (1) US20130012531A1 (es)
EP (1) EP2521550A4 (es)
JP (1) JP2013516472A (es)
KR (1) KR20120125244A (es)
CN (1) CN102781450A (es)
AU (1) AU2011203706A1 (es)
BR (1) BR112012016673A2 (es)
CA (1) CA2786328A1 (es)
CL (1) CL2012001852A1 (es)
CO (1) CO6561789A2 (es)
DO (1) DOP2012000174A (es)
EA (1) EA201290603A1 (es)
IL (1) IL220594A0 (es)
MA (1) MA33991B1 (es)
MX (1) MX2012007875A (es)
PE (1) PE20121523A1 (es)
SG (1) SG181826A1 (es)
TW (1) TW201201808A (es)
UY (1) UY33164A (es)
WO (1) WO2011085007A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AR081364A1 (es) * 2010-05-05 2012-08-29 Glaxo Wellcome Mfg Pte Ltd Composiciones farmaceuticas de pazopanib y metodos para su elaboracion
CA2818612C (en) 2010-11-19 2020-12-29 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
WO2013163758A1 (en) * 2012-05-01 2013-11-07 Boyd Shelley Romayne Methods for treating and diagnosing blinding eye diseases
AU2014236455B2 (en) 2013-03-14 2018-07-12 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
ES2813877T3 (es) 2013-08-28 2021-03-25 Crown Bioscience Inc Taicang Distintivos de expresión génica predictivos de la respuesta de un sujeto a un inhibidor multicinasa y métodos de uso de los mismos
MY182793A (en) 2014-08-08 2021-02-05 Forsight Vision4 Inc Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
WO2016200688A1 (en) * 2015-06-06 2016-12-15 Cloudbreak Therapeutics, Llc Compositions and methods for treating pterygium
US10323349B2 (en) * 2015-09-25 2019-06-18 Kyoudojyutaku Co., Ltd. Washing system
WO2017210130A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for improving glaucoma surgery success
EP3990433A4 (en) 2019-06-25 2023-07-26 Translatum Medicus Inc. METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE430742T1 (de) * 2000-12-21 2009-05-15 Smithkline Beecham Corp Pyrimidinamine als angiogenesemodulatoren
MX2008006379A (es) * 2005-11-29 2009-03-03 Smithkline Beecham Corp Metodo de tratamiento.
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
US8334239B2 (en) * 2007-07-10 2012-12-18 The Board Of Regents Of The University Of Texas System High affinity VEGF-receptor antagonists
US20090325959A1 (en) * 2008-06-26 2009-12-31 Vittitow Jason L Method for treating ophthalmic diseases using rho kinase inhibitor compounds
WO2011009016A1 (en) * 2009-07-16 2011-01-20 Glaxo Wellcome Manufacturing Pte Ltd Treatment method

Also Published As

Publication number Publication date
EP2521550A1 (en) 2012-11-14
SG181826A1 (en) 2012-07-30
PE20121523A1 (es) 2012-12-12
CA2786328A1 (en) 2011-07-14
DOP2012000174A (es) 2012-12-15
JP2013516472A (ja) 2013-05-13
WO2011085007A1 (en) 2011-07-14
IL220594A0 (en) 2012-08-30
CL2012001852A1 (es) 2012-11-30
EP2521550A4 (en) 2013-07-03
US20130012531A1 (en) 2013-01-10
EA201290603A1 (ru) 2013-03-29
TW201201808A (en) 2012-01-16
CN102781450A (zh) 2012-11-14
MA33991B1 (fr) 2013-02-01
MX2012007875A (es) 2012-08-03
CO6561789A2 (es) 2012-11-15
BR112012016673A2 (pt) 2018-06-05
KR20120125244A (ko) 2012-11-14
AU2011203706A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
CO6561789A2 (es) Método de tratamiento
CY1120334T1 (el) Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
IN2014DN09434A (es)
BR112015020389A2 (pt) compostos carbazol úteis como inibidores de bromodomínio
WO2013052699A3 (en) Novel quinoxaline inhibitors of pi3k
MD4539C1 (ro) 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MX342983B (es) 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il benzamidas como inhibidores de tirosina cinasa de bruton.
MX2015017201A (es) Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
UA113750C2 (xx) Склад (+)-2-$1-(3-етокси-4-метоксифеніл)-2-метансульфонілетил]-4-ацетиламіноізоіндолін-1,3-діону
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CR20140052A (es) Un derivado novedoso de 1,2,3,4-tetrahidroquinolina útil para el tratamiento de diabetes
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
EA201190337A1 (ru) Способ лечения
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
WO2013166037A9 (en) Non-retinoid antagonists for treatment of eye disorders
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20191121